Search

Participant taking VASODILATORS WITH DIURETICS, A MIXED GROUP within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY DIURETIC within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY DIURETIC within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANGIOTENSIN TYPE 2 ANTAGONISTS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking THIAZIDE DIURETICS WITHOUT K-SPARING AGENTS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking THIAZIDE DIURETICS WITH K-SPARING AGENTS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking THIAZIDE DIURETICS WITHOUT K-SPARING AGENTS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking THIAZIDE DIURETICS WITH K-SPARING AGENTS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SLOW-RELEASE DIHYDROPYRIDINES OTHER THAN NIFEDIPINE OR AMLOPIDINE within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY LIPID-LOWERING MEDICATION within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY LIPID-LOWERING MEDICATION within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ALPHA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ALPHA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ALPHA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ALPHA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking T-TYPE CALCIUM-CHANNEL BLOCKER within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SLOW-RELEASE CCBS = NIFSR OR DIHSR OR VERSR OR DLTSR OR AMLOD within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SLOW-RELEASE CCBS = NIFSR OR DIHSR OR VERSR OR DLTSR OR AMLOD within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY CALCIUM-CHANNEL BLOCKER = CCIR OR CCBSR OR CCBT within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY CALCIUM-CHANNEL BLOCKER = CCIR OR CCBSR OR CCBT within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL ANTI-INFLAMMATORY ASTHMA DRUGS (LEUKOTRIENE RECEPTOR ANTAGONISTS AND INHIBITORS OF LIPO-OXYGENASE) within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.